<DOC>
	<DOCNO>NCT00553514</DOCNO>
	<brief_summary>This Phase 2 , interventional , multi-center , randomize , assessor-blind , active-comparator , dose-finding study evaluate new investigational long-acting follicle stimulate hormone ( FSH ) oligo-anovulatory woman undergo ovulation induction ( OI ) . This study compare 4 dos investigational drug versus currently market drug follitropin alfa ( Gonal-f ® ) prefilled pen regard ovulation rate .</brief_summary>
	<brief_title>AS900672-Enriched Ovulation Induction</brief_title>
	<detailed_description>The study terminate Merck Serono take decision pursue development AS900672-enriched ovulation induction ( OI ) . This decision relate safety efficacy concern use AS900672-Enriched OI .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Oligoanovulation define menstrual period 35 day 6 month Spontaneous menses positive response progestin within prior 6 month response clomiphene citrate evidence ovulation within prior 6 month Age 18 36 year , inclusive , time informed consent signature Body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) , inclusive No clinically significant abnormality serum thyroid stimulate hormone ( TSH ) , dehydroepiandrosterone ( DHEAS ) , prolactin , FSH level early follicular phase . Subjects low TSH level receive replacement therapy could enrol discretion investigator local laboratory result ( thyroxine [ T4 ] ) demonstrate satisfactory thyroid function . Subjects receive stable dose dopamine agonist could enrol discretion investigator local laboratory result demonstrate adequate control prolactin level No clinically significant abnormality fast glucose fasting insulin level Normal uterine cavity presence least one ovary ipsilateral patent fallopian tube , determine mean hysterosalpingography , laparoscopy , hysteroscopy combination procedure within prior 3 year Papanicolaou ( PAP ) smear test without clinically significant abnormality within 6 month prior first screening procedure . If PAP smear do , must perform part screen procedure Negative pregnancy test prior randomization Male partner semen analysis demonstrate adequacy insemination via intercourse and/or intrauterine insemination ( IUI ) within 6 month prior first screening procedure . If semen analysis do , must perform part screen procedure Willing able comply protocol procedure , include pregnancy neonatal followup Voluntary provision write informed consent , prior trialrelated procedure part normal medical care , understand subject could withdraw consent time without prejudice future medical care , include willingness provide followup information baby bear part trial History &gt; =2 consecutive gonadotrophin stimulation cycle lead ovulation History clomiphene citrate stimulation cycle none lead ovulation Prior excessive response gonadotrophin stimulation , define development least 4 mature follicle ( great [ &gt; ] 17 mm ) cancellation OI cycle due excessive follicular response treatment FSH dose less 75 IU/day Previous severe ovarian hyperstimulation syndrome ( OHSS ) Administration gonadotrophin , clomiphene citrate , gonadotrophin release hormone ( GnRH ) analogue , tamoxifen aromatase inhibitor within prior 30 day Laparoscopic ovarian drilling and/or ovarian cauterization within prior 6 month Any contraindication pregnancy and/or carry pregnancy term A clinical pregnancy end miscarriage within prior 3 month History &gt; =3 consecutive miscarriage , due cause Abnormal gynecological bleeding undetermined origin Clinically significant abnormal finding uterine cavity evident transvaginal pelvic ultrasound perform screen Presence endometriosis , Grade III IV require treatment Ovarian cyst mean diameter &gt; 25 mm day randomization History suspicion ovarian , uterine mammary cancer Adrenal congenital hyperplasia , partial complete enzymatic block Use metformin insulin sensitize agent related infertility within prior 2 month Known allergy hypersensitivity human gonadotrophin preparation compound structurally similar medication administer trial Any contraindication gonadotrophin therapy Known suspect infection human immunodeficiency virus ( HIV ) , Hepatitis B C trial subject male partner Any active substance abuse history drug , medication alcohol abuse within 5 year Smoker consume 5 cigarette per day Serum testosterone ( central laboratory ) suggestive ovarian tumor Previously randomize trial participation another investigational drug clinical trial within prior 3 month Any medical condition , judgment investigator may interfere absorption , distribution , metabolism excretion rhFSH Clinically significant concurrent disease ( include diabetes mellitus autoimmune disease ) would compromise subject safety interfere study assessment clinically significant abnormal laboratory find</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Infertility</keyword>
	<keyword>Oligo-anovulation</keyword>
	<keyword>GONAL-f®</keyword>
	<keyword>AS900672-Enriched</keyword>
	<keyword>hyperglycosylated recombinant human follicle stimulate hormone ( r-hFSH )</keyword>
</DOC>